{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T05:34:43Z","timestamp":1789450483679,"version":"build-2803163510"},"reference-count":93,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["onlinecjc.ca","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.cjca.2018.11.005","type":"journal-article","created":{"date-parts":[[2018,11,15]],"date-time":"2018-11-15T15:29:50Z","timestamp":1542295790000},"page":"249-259","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Lipid Abnormalities in Persons Living With HIV Infection"],"prefix":"10.1016","volume":"35","author":[{"given":"David D.","family":"Waters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla Y.","family":"Hsue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2018.11.005_bib1","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with the human immunodeficiency virus: a systematic review and meta-analysis","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.11.005_bib2","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1161\/CIRCULATIONAHA.118.036211","article-title":"Time to recognize HIV infection as a major cardiovascular risk factor","volume":"138","author":"Hsue","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.11.005_bib3","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/S1473-3099(13)70271-8","article-title":"Metabolic disease in HIV infection","volume":"13","author":"Lake","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cjca.2018.11.005_bib4","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11904-016-0321-0","article-title":"Lipid abnormalities and inflammation in HIV infection","volume":"13","author":"Funderburg","year":"2016","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.cjca.2018.11.005_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.atherosclerosis.2015.03.019","article-title":"High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis","volume":"240","author":"D\u2019Ascenzo","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2018.11.005_bib6","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1001\/jama.289.22.2978","article-title":"Impact of HIV infection and HAART on serum lipids in men","volume":"289","author":"Riddler","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2018.11.005_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11745-009-3369-4","article-title":"Lipid abnormalities in a never-treated HIV-1 subtype C-infected African population","volume":"45","author":"Fourie","year":"2010","journal-title":"Lipids"},{"key":"10.1016\/j.cjca.2018.11.005_bib8","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults. 2016 Recommendations of the International Antiviral Society\u2013USA Panel","volume":"316","author":"G\u00fcnthard","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2018.11.005_bib9","first-page":"328","article-title":"Premature and accelerated aging: HIV or HAART?","volume":"3","author":"Smith","year":"2012","journal-title":"Front Genet"},{"key":"10.1016\/j.cjca.2018.11.005_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00126334-200001010-00005","article-title":"Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection","volume":"23","author":"Mulligan","year":"2000","journal-title":"J\u00a0Acquir Immun Defic Syndr"},{"key":"10.1016\/j.cjca.2018.11.005_bib11","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/QAD.0000000000001837","article-title":"Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor-associated hypercholesterolaemia","volume":"32","author":"Leyes","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.11.005_bib12","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1086\/381783","article-title":"Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different drugs associated with different lipid profiles?","volume":"189","author":"Fontas","year":"2004","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cjca.2018.11.005_bib13","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/649897","article-title":"Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study","volume":"201","author":"Worm","year":"2010","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cjca.2018.11.005_bib14","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.CIR.100.7.700","article-title":"Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors","volume":"100","author":"P\u00e9riard","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.11.005_bib15","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/jmv.23543","article-title":"Improved metabolic profile after switch to darunavir\/ritonavir in HIV positive patients previously on protease inhibitor therapy","volume":"85","author":"Ucciferri","year":"2013","journal-title":"J\u00a0Med Virol"},{"key":"10.1016\/j.cjca.2018.11.005_bib16","series-title":"Braunwald\u2019s Heart Disease. A textbook of cardiovascular medicine","first-page":"1651","article-title":"Cardiovascular abnormalities in HIV-infected individuals","author":"Hsue","year":"2019"},{"key":"10.1016\/j.cjca.2018.11.005_bib17","first-page":"1","article-title":"Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1","volume":"161","author":"Daar","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2018.11.005_bib18","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0140-6736(11)60936-7","article-title":"Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial","volume":"378","author":"Molina","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.11.005_bib19","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study","volume":"67","author":"Sax","year":"2014","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cjca.2018.11.005_bib20","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1097\/QAD.0b013e32823644ff","article-title":"Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era","volume":"21","author":"Joy","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.11.005_bib21","doi-asserted-by":"crossref","first-page":"R185","DOI":"10.1530\/EJE-13-0967","article-title":"Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients","volume":"170","author":"Srinivasa","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.cjca.2018.11.005_bib22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(12)61853-4","article-title":"Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study","volume":"381","author":"Raffi","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.11.005_bib23","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1097\/QAD.0000000000000762","article-title":"A\u00a0prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness","volume":"29","author":"Stein","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.11.005_bib24","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0021-9150(01)00601-3","article-title":"Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels","volume":"160","author":"Vitek","year":"2002","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cjca.2018.11.005_bib25","article-title":"Bilirubin is inversely associated with cardiovascular disease among HIV-positive and HIV-negative individuals in VACS (Veterans Aging Cohort Study)","volume":"7","author":"Marconi","year":"2018","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2018.11.005_bib26","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1017\/gheg.2018.7","article-title":"HIV treatment is associated with a two-fold higher probability of raised triglycerides: Pooled Analyses in 21 023 individuals in sub-Saharan Africa","volume":"3","author":"Ekoru","year":"2018","journal-title":"Glob Health Epidemiol Genom"},{"key":"10.1016\/j.cjca.2018.11.005_bib27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nri3793","article-title":"Cholesterol, inflammation and innate immunity","volume":"15","author":"Tall","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cjca.2018.11.005_bib28","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/nm1511","article-title":"Microbial translocation is a cause of systemic immune activation in chronic HIV infection","volume":"12","author":"Brenchley","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.cjca.2018.11.005_bib29","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1161\/CIRCULATIONAHA.108.810721","article-title":"Inflammation impairs reverse cholesterol transport in\u00a0vivo","volume":"119","author":"McGillicudy","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.11.005_bib30","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1097\/QAD.0000000000000739","article-title":"Monocytes from HIV-infected individuals show impaired cholesterol efflux and increased foam cell formation after transendothelial migration","volume":"29","author":"Maisa","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.11.005_bib31","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/infdis\/jiq118","article-title":"Plasma levels of soluble CD14 independently predict mortality in HIV infection","volume":"203","author":"Sandler","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cjca.2018.11.005_bib32","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/infdis\/jir520","article-title":"Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients","volume":"204","author":"Burdo","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cjca.2018.11.005_bib33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2012.6698","article-title":"Arterial inflammation in patients with HIV","volume":"308","author":"Subramanian","year":"201225","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2018.11.005_bib34","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.11.005_bib35","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1089\/aid.2014.0239","article-title":"Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens","volume":"31","author":"Munger","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"key":"10.1016\/j.cjca.2018.11.005_bib36","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/QAI.0000000000000566","article-title":"Oxidized LDL levels are increased in HIV infection and may drive monocyte activation","volume":"69","author":"Zidar","year":"2015","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cjca.2018.11.005_bib37","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1097\/QAD.0000000000001238","article-title":"Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection","volume":"30","author":"Kelesidis","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.11.005_bib38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1468-1293.2009.00766.x","article-title":"Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation","volume":"11","author":"Parra","year":"2010","journal-title":"HIV Med"},{"key":"10.1016\/j.cjca.2018.11.005_bib39","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1086\/652749","article-title":"Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection","volume":"201","author":"Neuhaus","year":"2010","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cjca.2018.11.005_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155100","article-title":"Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy","volume":"11","author":"Grund","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2018.11.005_bib41","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/S1473-3099(07)70287-6","article-title":"HIV-associated dyslipidaemia: pathogenesis and treatment","volume":"7","author":"Oh","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cjca.2018.11.005_bib42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1152\/jappl.2001.90.1.133","article-title":"Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy","volume":"90","author":"Yarasheski","year":"2001","journal-title":"J\u00a0Appl Physiol"},{"key":"10.1016\/j.cjca.2018.11.005_bib43","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S0140-6736(98)00022-1","article-title":"Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities","volume":"352","author":"Henry","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.11.005_bib44","first-page":"146","article-title":"HIV-related cardiovascular disease, statins, and the REPRIEVE trial","volume":"23","author":"Gilbert","year":"2015","journal-title":"Top Antivir Med"},{"key":"10.1016\/j.cjca.2018.11.005_bib45","doi-asserted-by":"crossref","first-page":"458","DOI":"10.7326\/M13-1754","article-title":"Associations between HIV infection and subclinical coronary atherosclerosis","volume":"160","author":"Post","year":"2014","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2018.11.005_bib46","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1016\/S2352-3018(14)00032-0","article-title":"Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial","volume":"2","author":"Lo","year":"2015","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cjca.2018.11.005_bib47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.phrs.2016.06.005","article-title":"A\u00a0PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients","volume":"111","author":"Banach","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.cjca.2018.11.005_bib48","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/infdis\/jiu012","article-title":"Effect of 24 weeks of statin therapy on systemic and vascular inflammation in HIV-infected subjects receiving antiretroviral therapy","volume":"209","author":"Eckard","year":"2014","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cjca.2018.11.005_bib49","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12879-018-3162-1","article-title":"Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis","volume":"18","author":"Uthman","year":"2018","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cjca.2018.11.005_bib50","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/cid\/cit053","article-title":"Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death","volume":"56","author":"Overton","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cjca.2018.11.005_bib51","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2018.11.005_bib52","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1097\/QAD.0000000000000360","article-title":"2013 American College of Cardiology\/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with\/without subclinical high-risk coronary plaque","volume":"28","author":"Zanni","year":"2014","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.11.005_bib53","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005995","article-title":"Utility of 2013 American College of Cardiology\/American Heart Association cholesterol guidelines in HIV-infected adults with carotid atherosclerosis","volume":"10","author":"Phan","year":"2017","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.cjca.2018.11.005_bib54","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/2047487315579291","article-title":"An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study","volume":"23","author":"Friis-M\u00f8ller","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.cjca.2018.11.005_bib55","author":"Grundy"},{"key":"10.1016\/j.cjca.2018.11.005_bib56","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/j.amjcard.2015.03.025","article-title":"A\u00a0systematic review of the usefulness of statin therapy in HIV-infected patients","volume":"115","author":"Feinstein","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2018.11.005_bib57","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/FJC.0b013e31817b5b5a","article-title":"Effects of atazanavir\/ritonavir or fosamprenavir\/ritonavir on the pharmacokinetics of rosuvastatin","volume":"51","author":"Busti","year":"2008","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2018.11.005_bib58","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cjca.2016.10.019","article-title":"An evidence-based guide to cholesterol-lowering guidelines","volume":"33","author":"Waters","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cjca.2018.11.005_bib59","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11908-018-0628-7","article-title":"Benefits and risks of statin therapy in an HIV-infected population","volume":"20","author":"Mosepele","year":"2018","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.cjca.2018.11.005_bib60","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/S2352-3018(17)30075-9","article-title":"Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial","volume":"4","author":"Aberg","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cjca.2018.11.005_bib61","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/QAD.0000000000001427","article-title":"Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV","volume":"31","author":"Toribio","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.11.005_bib62","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1089\/apc.2017.0304","article-title":"Evaluation of statin eligibility, prescribing practices, and therapeutic responses using ATP III, ACC\/AHA, and NLA dyslipidemia treatment guidelines in a large urban cohort of HIV-infected outpatients","volume":"32","author":"Levy","year":"2018","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.cjca.2018.11.005_bib63","article-title":"Disparities in the quality of cardiovascular care between HIV-infected versus HIV-uninfected adults in the United States: a cross-sectional study","volume":"6","author":"Ladapo","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2018.11.005_bib64","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1086\/592116","article-title":"Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy","volume":"47","author":"Wohl","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cjca.2018.11.005_bib65","article-title":"HIV and hepatitis C-coinfected patients have lower low-density lipoprotein cholesterol despite higher proprotein convertase subtilisin kexin 9 (PCSK9): an apparent \u201cPCSK9-lipid paradox.\u201d","volume":"5","author":"Kohli","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.cjca.2018.11.005_bib67","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S0140-6736(09)62041-9","article-title":"Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials","volume":"375","author":"Eron","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.11.005_bib68","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1097\/QAD.0000000000001675","article-title":"Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk","volume":"31","author":"Gatell","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.11.005_bib69","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/hiv.12362","article-title":"Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial","volume":"17","author":"Lee","year":"2016","journal-title":"HIV Med"},{"key":"10.1016\/j.cjca.2018.11.005_bib70","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/QAI.0b013e3181b0610e","article-title":"Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir","volume":"52","author":"Busse","year":"2009","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cjca.2018.11.005_bib71","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/QAI.0b013e31815bace2","article-title":"Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV infected subjects on antiretroviral therapy. Results of ACTG A5186","volume":"47","author":"Gerber","year":"2008","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cjca.2018.11.005_bib72","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/QAI.0b013e3182a60e82","article-title":"Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care","volume":"64","author":"Mu\u00f1oz","year":"2013","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cjca.2018.11.005_bib73","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2165\/00002018-200831100-00002","article-title":"Drug-induced pancreatitis: incidence, management and prevention","volume":"31","author":"Balani","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.cjca.2018.11.005_bib74","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cjca.2018.11.005_bib75","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2018.11.005_bib76","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2018.11.005_bib77","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.jacc.2018.09.038","article-title":"IL-1\u03b2 inhibition reduces atherosclerotic inflammation in HIV\u00a0infection","volume":"72","author":"Hsue","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cjca.2018.11.005_bib78","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cjca.2018.11.005_bib79","author":"Ridker"},{"key":"10.1016\/j.cjca.2018.11.005_bib80","author":"Hsue"},{"key":"10.1016\/j.cjca.2018.11.005_bib81","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1161\/ATVBAHA.118.311807","article-title":"Brachial artery echogenicity and grayscale texture changes in HIV-infected individuals receiving low-dose methotrexate: AIDS Clinical Trial Group Study","volume":"38","author":"Stein","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cjca.2018.11.005_bib82","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s11904-014-0219-7","article-title":"Metabolic syndrome, diabetes, and cardiovascular risk in HIV","volume":"11","author":"Nix","year":"2014","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.cjca.2018.11.005_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044575","article-title":"Risk of diabetes mellitus in persons with and without HIV: a Danish nationwide population based cohort study","volume":"7","author":"Rasmussen","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2018.11.005_bib84","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/QAD.0000000000001700","article-title":"High rates of hypertension, diabetes, elevated low-density lipoprotein cholesterol, and cardiovascular disease risk factors in HIV-infected patients in Malawi","volume":"32","author":"Mathabire R\u00fccker","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.cjca.2018.11.005_bib85","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/cid\/cit652","article-title":"Prehypertension, hypertension, and the risk of acute myocardial infarction in HIV-infected and -uninfected veterans","volume":"58","author":"Armah","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cjca.2018.11.005_bib86","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1161\/CIRCULATIONAHA.109.898585","article-title":"Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons","volume":"121","author":"Choi","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2018.11.005_bib87","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/infdis\/jiw342","article-title":"Renal impairment and cardiovascular disease in HIV-positive individuals: The D:A:D study","volume":"214","author":"Ryom","year":"2016","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cjca.2018.11.005_bib88","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3018(15)00211-8","article-title":"Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study","volume":"3","author":"Mocroft","year":"2016","journal-title":"Lancet HIV"},{"key":"10.1016\/j.cjca.2018.11.005_bib89","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/cid\/cis933","article-title":"Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study","volume":"56","author":"Helleberg","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cjca.2018.11.005_bib90","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/QAI.0000000000001007","article-title":"Behavioral interventions for tobacco use in HIV-infected smokers: a meta-analysis","volume":"72","author":"Keith","year":"2016","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.cjca.2018.11.005_bib91","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1468-1293.2011.00984.x","article-title":"Outcome of smoking cessation counselling of HIV-positive persons by HIV care physicians","volume":"13","author":"Huber","year":"2012","journal-title":"HIV Med"},{"key":"10.1016\/j.cjca.2018.11.005_bib92","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1089\/apc.2011.0199","article-title":"Safety and tolerability of varenicline tartrate (Champix\u00ae\/Chantix\u00ae) for smoking cessation in HIV-infected subjects: a pilot open-label study","volume":"26","author":"Cui","year":"2012","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.cjca.2018.11.005_bib93","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/09540121.2016.1201195","article-title":"An HIV-tailored quit-smoking counselling pilot intervention targeting depressive symptoms plus nicotine replacement therapy","volume":"29","author":"Balfour","year":"2017","journal-title":"AIDS Care"},{"key":"10.1016\/j.cjca.2018.11.005_bib94","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1468-1293.2010.00901.x","article-title":"Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study","volume":"12","author":"Petoumenos","year":"2011","journal-title":"HIV Med"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X18312790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X18312790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T02:55:05Z","timestamp":1662432905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X18312790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":93,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0828282X18312790"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2018.11.005","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid Abnormalities in Persons Living With HIV Infection","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2018.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}